rifampicin

P3, N=422, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jan 2031 --> Jun 2031 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jul 2030 --> Dec 2030

P1, N=32, Completed, Cascade Pharmaceuticals, Inc | Trial primary completion date: Feb 2027 --> Mar 2026 | Not yet recruiting --> Completed | Trial completion date: Feb 2027 --> Apr 2026

While modulating Bcl-2 pathways can be effective in MS, future research should aim to provide greater clarification and to design precision-based drugs capable of neuroprotective effects.

Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). From Year 1-5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI- patients. The absence of observed TB risk in guselkumab-treated patients suggests IL-23 inhibitors may be better treatment options than TNFi in high-risk patients, including those in TB-endemic regions.

P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

Treatment of LS180 human colon adenocarcinoma cells, a commonly used human PXR (hPXR) experimental model, with a hPXR agonist (rifampicin, T0901317, SR12813, ritonavir, or paclitaxel) increased AOX1 mRNA expression by 5.2-, 10.2-, 4.7-, 2.2-, and 6.5-fold, respectively, and increased a prototypic hPXR target gene (CYP3A4 mRNA) expression by 9.5-, 13.5-, 7.2-, 3.4-, and 18.0-fold, respectively...It was abolished by actinomycin D, indicating the mRNA increase occurred by a transcriptional mechanism...Control analysis indicated that PCN increased mouse PXR-regulated Cyp3a11 mRNA and Cyp3a-mediated enzyme activity. Overall, our novel data provide evidence for a role of PXR in AOX1 gene expression.

P1, N=14, Not yet recruiting, Merck Sharp & Dohme LLC

P1, N=32, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed

However, when acting as a victim, co-administration with strong CYP3A4 inhibitors (itraconazole, ketoconazole) increased flumatinib AUC0-72h by approximately 12-fold (AUCR = 11.65-12.96), whereas rifampicin decreased Cmax and AUC0-72h by 2.4- and 4.7-fold (CmaxR = 0.41, AUCR = 0.21), respectively. Flumatinib shows negligible perpetrator potential but is highly sensitive to CYP3A4 modulation. PBPK-informed DDI assessment supports cautious co-administration with strong CYP3A4 inhibitors or inducers and guides its rational clinical use.

P1, N=32, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=72 --> 32

P4, N=5, Terminated, West Virginia University | N=20 --> 5 | Enrolling by invitation --> Terminated; The study was stopped because all five participants were lost to follow-up before completing treatment or any assessments, leaving no outcome data available and making continuation of the trial infeasible.

DDI simulations indicated that vcMMAE-based ADCs act as victims with low-to-moderate sensitivity; coadministration with ketoconazole increased MMAE exposure by 45%-85%, whereas rifampin reduced it by 49%-56%. Conversely, as perpetrators, the ADCs exhibited a negligible impact on the PK of midazolam and digoxin, suggesting a low risk of MMAE-mediated inhibition or induction of CYP3A4 and P-gp...By quantitatively assessing the drug-drug interaction potential of valine-citrulline-monomethyl auristatin E-based antibody-drug conjugates as both victims and perpetrators, this work provides a scientifically justified tool to guide regulatory labeling. Importantly, this framework supports clinical drug-drug interaction trial waivers, thereby streamlining the development of next-generation targeted therapeutics.